Lixoft is a French company founded in 2011 after a research program in mathematics and statistics at Inria and Ecole Polytechnique. Lixoft develops software for the modeling and simulation of clinical trials, patient populations and individualized treatment effects. Its chairman Dr Jérôme Kalifa explains the benefits and future of these technologies.
Jérôme Kalifa presents the concept of in silico modeling in drug development. As opposed to in vivo or in vitro, experiments are simulated with computer models. Software libraries provide mathematical and statistical models to evaluate the efficacy of a treatment on a disease, and the interindividual variabilities in treatment response for every patient. Such virtual clinical trials are used for evaluating and optimizing real clinical studies, whose results help in turn to build more advanced and accurate models.
Besides sheer performance, Lixoft designs these technologies to make them as intuitive and easy to use as possible, ensuring they can be shared in collaborations involving physicians, modelers, statisticians, pharmacometricians, in both pharmaceutical companies and hospitals.
Modelling and simulation are evolving rapidly due to the increasing complexity of new treatments and the advent of new types of data, massive (genomics, proteomics…), unusual or heterogeneous: patient monitoring at home, health records, new sensors… Machine learning methods are therefore incorporated to complete the predictive, personalized models of treatment response for every patient.
Lixoft is merging traditional approaches of clinical studies and pharmacology with new advances in decentralized clinical trials at home, digital biomarkers and individual precision medicine. The mission of the company is to multiply and consolidate such bridges.
